医学
倾向得分匹配
糖皮质激素
回顾性队列研究
队列
强的松
皮质类固醇
肺炎
呼吸系统
内科学
队列研究
混淆
逻辑回归
常见可变免疫缺陷
优势比
子群分析
抗体
临床病理学
免疫球蛋白G
多元分析
呼吸道感染
儿科
甲基强的松龙
外科
置信区间
呼吸机相关性肺炎
临床试验
机械通风
药物治疗
作者
Zhiyuan Zhong,Pu Rui,Ran Yao,Xiaoyu Li,Yuqing Ou,Liangkang Lin,W J Yu,Junfeng Xie,Tianqi Liang
标识
DOI:10.3389/fmed.2026.1846957
摘要
Background: The effectiveness of intravenous immunoglobulin (IVIG) in the treatment of severe respiratory syncytial virus pneumonia (SRSVP) remains a topic of ongoing debate. This study aimed to evaluate the association of IVIG on the duration of hospitalization and the use of corticosteroids in pediatric cases of SRSVP. Methods: = 157), while generalized estimating equations (GEE) /generalized linear models (GZLM) were utilized within the matched cohort to evaluate the independent association between IVIG use and clinical outcomes (hospitalization duration and corticosteroid use). Results: Results showed that intravenous immunoglobulin (IVIG) treatment failed to reduce the duration of corticosteroid use, corticosteroid dosage, or length of hospital stay (OR = 4.634; OR = 4.667; OR = 2.566). Propensity score matching (PSM) successfully generated 41 well-balanced pairs. In the GEE/GZLM analysis (which further corrected for residual baseline imbalances in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine), IVIG treatment still failed to reduce the duration of glucocorticoid use (OR = 3.229, 95% CI: 1.267-8.232), reduce glucocorticoid dosage (OR = 2.653, 95% CI: 1.063-6.619), or shorten the length of hospital stay (OR = 4.375, 95% CI: 1.581-12.108). Furthermore, subgroup analysis showed that in infants <6 months of age, IVIG treatment did not shorten hospital stay and was not associated with glucocorticoid use outcomes. Conclusion: In conclusion, intravenous immunoglobulin (IVIG) treatment did not shorten hospital stays or reduce the use of glucocorticoids in children with severe respiratory syncytial virus pneumonia (SRSVP). Therefore, it is necessary to reassess the value of IVIG in the treatment of SRSVP.
科研通智能强力驱动
Strongly Powered by AbleSci AI